Device Trial Radar · NCT07756242
Pharmacokinetic Study of Therapeutic Plasma Exchange
Last checked: Nov 20, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Nov 2026
Primary completion
Nov 2027
Study completion Feb 2028
Sponsor
- Lead sponsor
- University of ChicagoAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 10, 2026
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to characterize the pharmacokinetics of one or more ICIs during and after TPE/PLEX in patients with severe irAEs.
Conditions
- Immune-related Adverse Event
Interventions
Spectra Optia Apheresis SystemDevice
Therapeutic plasma exchange (using the Spectra Optia Apheresis System) will be done according to standard of care.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in circulating ICI concentration during and after TPE/PLEXTime frame: Baseline to Day 90
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The University of Chicago
Chicago, Illinois
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.